Folate augmentation of treatment - Evaluation for depression (folated): Randomised trial and economic evaluation

Health Technology Assessment

Volumn 18, Issue 48, 2014, Pages 1-159

  Bedson, Emma ^a   Bell, Diana ^b   Carr, Daniel ^a   Carter, Ben ^c   Hughes, Dyfrig ^d   Jorgensen, Andrea ^a   Lewis, Helen ^e   Lloyd, Keith ^f   Mccaddon, Andrew ^d   Moat, Stuart ^g   Pink, Joshua ^d   Pirmohamed, Munir ^a   Roberts, Seren ^d   Russell, Ian ^f   Sylvestre, Yvonne ^h   Tranter, Richard ⁱ   Whitaker, Rhiannon ^d   Wilkinson, Clare ^d   Williams, Nefyn ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d BANGOR UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

^f SWANSEA UNIVERSITY   (United Kingdom)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; FOLIC ACID; HOMOCYSTEINE; PLACEBO;

ALCOHOLISM; ARTICLE; BECK DEPRESSION INVENTORY; BIOCHEMISTRY; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL RESEARCH; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MISUSE; ECONOMIC EVALUATION; EXPLORATORY RESEARCH; FAMILY PLANNING; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; GENERAL PRACTITIONER; GENETIC POLYMORPHISM; HUMAN; INFORMED CONSENT; INTERVIEW; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENTAL HEALTH; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PREGNANCY; PRIMARY MEDICAL CARE; PSYCHIATRIST; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SECONDARY HEALTH CARE; SENSITIVITY ANALYSIS; SHORT FORM 12; STANDARDIZATION; SUICIDAL BEHAVIOR; TERMINAL DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNIVERSITY HOSPITAL; ADULT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETICS; MALE; METABOLISM; RISK FACTOR; TREATMENT OUTCOME; WALES;

ADULT; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSION; FEMALE; FOLIC ACID; HUMANS; MALE; POLYMORPHISM, GENETIC; RISK FACTORS; TREATMENT OUTCOME; WALES;

EID: 84905017800     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18480     Document Type: Article

References (187)

1. World Health Organization and World Organization of Family Doctors. Integrating Mental Health into Primary Care: A Global Perspective. Geneva, Switzerland: WHO; 2008.
2. World Health Organization. Investing in Mental Health. Geneva, Switzerland: WHO; 2003.
3. Sweet D. In Beaumont J, editor. Health Clinical Research Centre. London: Office for National Statistics; 2011.
4. World Health Organization. Depression. Geneva, Switzerland: WHO; 2011. URL: www.who.int/topics/depression/en/(accessed March 2013).
5. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79. http://dx.doi.org/10.1016/j.euroneuro.2011.07.018
6. Kemp PA, Davidson J. Routes onto Incapacity Benefit: Findings from a Survey of Recent Claimants. Leeds: Department for Work and Pensions; 2007.
7. Henderson J, Henderson G, Lavikainen J, McDaid D. Actions Against Depression: Improving Mental Health and Well Being by Combating the Adverse Health, Social and Economic Consequences of Depression. Luxembourg: European Commission; 2004.
8. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004;49:124-38.
9. National Collaborating Centre for Mental Health. Depression: The NICE Guidance on the Treatment and Management of Depression in Adults. London: British Psychological Society and Royal College of Psychiatrists; 2010.
10. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-92. http://dx.doi.org/10.1001/archpsyc.55.7.580
11. Royal College of Psychiatrists. The Psychological Care of Medical Patients: Practical Guide. London: Royal College of Psychiatrists; 2003.
12. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183:514-19. http://dx.doi.org/10.1192/bjp.183.6.514
13. Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Rep 2005;7:441-6. http://dx.doi.org/10.1007/s11920-005-0065-9
14. Coryell W, Akiskal HS, Leon AC, Winokur G, Maser JD, Mueller TI, et al. The time course of nonchronic major depressive disorder: uniformity across episodes and samples. Arch Gen Psychiatry 1994;51:405-10. http://dx.doi.org/10.1001/archpsyc.1994.03950050065007
15. Posternak MA, Miller I. Untreated short-term course of major depression: meta-analysis of outcomes from studies using wait-list control groups. J Affect Disord 2001;66:139-46. http://dx.doi.org/10.1016/S0165-0327(00)00304-9
16. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 1984;252:788-92. http://dx.doi.org/10.1001/jama.1984.03350060032024
17. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700. http://dx.doi.org/10.1001/archpsyc.55.8.694
18. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96. http://dx.doi.org/10.1177/0269881107088441
19. Donoghue J. Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000;101:57-61. http://dx.doi.org/10.1111/j.1600-0447.2000.tb10949.x
20. Mulrow CD, Williams JWJ, Trivedi M, Chiquette E, Aguilar C, Cornell JE, et al. Treatment of Depression-newer Pharmacotherapies: Summary. Technology Assessments 7. Rockville, MD: US Agency for Healthcare Research and Quality; 1999.
21. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7. http://dx.doi.org/10.1001/jama.287.14.1840
22. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: STAR*D report. Am J Psychiatry 2006;163:1905-17. http://dx.doi.org/10.1176/appi.ajp.163.11.1905
23. Simon GE, Goldberg DP, von Korff M, Ustun TB. Understanding crossnational differences in depression prevalence. Psycholog Med 2002;32:585-94.
24. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. http://dx.doi.org/10.1001/jama.289.23.3095
25. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(Suppl.):28-34.
26. Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H. Recurrence of bipolar disorders and major depression: life-long perspective. Eur Arch Psychiatry Clin Neurosci 2003;253:236-40.
27. Roberts SH, Bedson E, Tranter R. Half-baked? B vitamins and depression (editorial). Am J Clin Nutr 2010;92:269-70.
28. Pauwels EKJ. The folate puzzle: IV - folate and depression. Drugs Future 2008;33:591-5. http://dx.doi.org/10.1358/dof.2008.033.07.1236397
29. Sarris J, Schoendorfer N, Kavanagh DJ. Major depressive disorder and nutritional medicine: review of monotherapies and adjuvant treatments. Nutr Rev 2009;67:125-31. http://dx.doi.org/10.1111/j.1753-4887.2009.00180.x
30. Robinson DS. Vitamins, monoamines, and depression. Prim Psychiatry 2009;16:19-21.
31. Office of Dietary Supplements. Folate: Dietary Supplement Fact Sheet. Bethesda, MD: National Institutes of Health; 2009. URL: www.ods.od.nih.gov/factsheet/folate (accessed March 2013).
32. Morris DW, Trivedi M, Rush AJ. Folate and unipolar depression. J Altern Complement Med 2008;14:277-85. http://dx.doi.org/10.1089/acm.2007.0663
33. Astorg P, Couthouis A, De Courcy GP, Bertrais S, Arnault N, Meneton P, et al. Association of folate intake with the occurrence of depressive episodes in middle-aged French men and women. Br J Nutr 2008;100:183-7. http://dx.doi.org/10.1017/S0007114507873612
34. Sanchez-Villegas A, Doreste J, Schlatter J, Pla J, Bes-Rastrollo M, Martinez-Gonzalez MA. Association between folate, vitamin B6 and vitamin B12 intake and depression in the SUN cohort study. J Hum Nutr Diet 2009;22:122-33.
35. Wantanabe H, Konno Y, Matsumato M, Nomachi S, Masaki K, Okayama H. Relationship of dietary folate intake, serum folate, and homocysteine with depression in young women. J Obstet Gynecol Neonatal Nurs 2011;40:S92-3.
36. Tolmunen T, Hintikka J, Ruusunen A, Voutilainen S, Tanskanen A, Valkonen VP, et al. Dietary folate and the risk of depression in Finnish middle-aged men: prospective follow-up study. Psychother Psychosom 2004;74:334-9.
37. Carney MWP. Serum folate values in 423 psychiatric patients. BMJ 1967;4:512-16. http://dx.doi.org/10.1136/bmj.4.5578.512
38. Ng T, Feng L, Niti M, Kua E, Yap K. Folate, vitamin B12, homocysteine, and depressive symptoms in a population sample of older Chinese adults. J Am Geriatr Soc 2009;57:871-6. http://dx.doi.org/10.1111/j.1532-5415.2009.02229.x
39. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Acta Psychiatr Scand 1989;80:78-82. http://dx.doi.org/10.1111/j.1600-0447.1989.tb01303.x
40. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition 2000;16:544-6. http://dx.doi.org/10.1016/S0899-9007(00)00327-0
41. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH. Depression and folate status in the US population. Psychother Psychosom 2003;72:80-7. http://dx.doi.org/10.1159/000068692
42. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005;19:59-65. http://dx.doi.org/10.1177/0269881105048899
43. Kim J-M, Stewart R, Kim S-W, Yang S-J, Shin I-S, Yoon J-S. Predictive value of folate, vitamin B12 and homocysteine levels in late-life depression. Br J Psychiatry 2008;192:268-74. http://dx.doi.org/10.1192/bjp.bp.107.039511
44. Skarupski KA, Tangney C, Li H, Ouyang B, Evans DA, Morris MC. Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. Am J Clin Nutr 2010;92:330-5. http://dx.doi.org/10.3945/ajcn.2010.29413
45. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 2007;61:631-7. http://dx.doi.org/10.1136/jech.2006.050385
46. Kendrick T, Dunn N, Robinson S, Oestmann A, Godfrey K, Cooper C, et al. A longitudinal study of blood folate levels and depressive symptoms among young women in the Southampton Women's Survey. J Epidemiol Community Health 2008;62:966-72. http://dx.doi.org/10.1136/jech.2007.069765
47. Payne M, Jamerson BD, Potocky CF, et al. Natural food folate and late-life depression. J Nutr Elder 2009;28:348-58. http://dx.doi.org/10.1080/01639360903417181
48. Walker JG, Mackinnon AJ, Batterham P, Jorm AF, Hickie I, McCarthy A, et al. Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial. Br J Psychiatry 2010;197:45-54. http://dx.doi.org/10.1192/bjp.bp.109.075291
49. Ford AH, Flicker L, Thomas J, Norman P, Jamrozik K, Almeida OP. Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men: results from a 2-year placebo-controlled randomized trial. J Clin Psychiatry 2008;69:1203-9. http://dx.doi.org/10.4088/JCP.v69n0801
50. Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst Rev 2003;2:CD003390. http://dx.doi.org/10.1002/14651858.CD003390
51. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1103-12. http://dx.doi.org/10.1016/j.pnpbp.2005.06.021
52. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099-101. http://dx.doi.org/10.1176/appi.ajp.159.12.2099
53. Sachdev PS, Parslow RA, Lux O, Salonikas C, Wen W, Naidoo D, et al. Relationship of homocysteine, folic acid and vitamin B12 with depression in a middle-aged community sample. Psycholog Med 2005;35:529-38. http://dx.doi.org/10.1017/S0033291704003721
54. Tolmunen T, Hintikka J, Voutilainen S, Ruusunen A, Alfthan G, Nyyssonen K, et al. Association between depressive symptoms and serum concentrations of homocysteine in men: population study. Am J Clin Nutr 2004;80:1574-8.
55. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry 2008;65:1286-94. http://dx.doi.org/10.1001/archpsyc.65.11.1286
56. Scott J, Dinn J, Wilson P, Weir D. Pathogenesis of subacute combined degeneration: result of methyl group deficiency. Lancet 1981;2:334-7. http://dx.doi.org/10.1016/S0140-6736(81)90649-8
57. Selhub J, Morris MS, Jacques PF. In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci U S A 2007;104:1995-2000. http://dx.doi.org/10.1073/pnas.0709487104
58. Quinlivan EP. In vitamin B12 deficiency, higher serum folate is associated with increased homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci U S A 2008;105:1387-8. http://dx.doi.org/10.1073/pnas.0711541105
59. Botez MI, Young SN, Bachevalier J, Gauthier S. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature 1979;278:182-3. http://dx.doi.org/10.1038/278182a0
60. Lazarou C, Kapsou M. The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract 2010;16:161-6. http://dx.doi.org/10.1016/j.ctcp.2010.01.003
61. Parker G, Mitchell P, Wilhelm K, Menkes DB, Snowdon J, Schweitzer I, et al. Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. Aus N Z J Psychiatry 1999;33:874-81. http://dx.doi.org/10.1046/j.1440-1614.1999.00648.x
62. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426-8.
63. Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with SSRI or tricyclic antidepressant. J Clin Psychopharmacol 2003;23:309-13. http://dx.doi.org/10.1097/01.jcp.0000084024.22282.cd
64. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomised controlled trials. J Psychopharmacol 2004;18:251-6.
65. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: randomised, placebo controlled trial. J Affect Disord 2000;60:121-30. http://dx.doi.org/10.1016/S0165-0327(00)00153-1
66. Godfrey PSA, Toone BK, Carney MWP, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-5. http://dx.doi.org/10.1016/0140-6736(90)91942-4
67. Basoglu C, Ates M, Algul A, Ipcioglu OM, Gecici O, Yilmaz O, et al. Adjuvant folate with escitalopram treatment and homocysteine, folate, vitamin B-12 levels in patients with major depressive disorder. Bull Clin Psychopharmacol 2009;19:135-42.
68. Resler G, Lavie R, Campos J, Mata S, Urbina M, Garcia A, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation 2008;15:145-52.
69. Christensen H, Aiken A, Batterham PJ, Walker J, Mackinnon AJ, Fenech M, et al. No clear potentiation of antidepressant medication effects by folic acid and vitamin B12 in a large community sample. J Affect Disord 2011;130:37-45. http://dx.doi.org/10.1016/j.jad.2010.07.029
70. Ford AH, Flicker L, McCaul K, van Bockxmeer F, Hegarty S, Hirani V, et al. The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life. Trials 2010;11:8. http://dx.doi.org/10.1186/1745-6215-11-8
71. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 2011;16:193-201. http://dx.doi.org/10.1038/mp.2009.124
72. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry 2011;16:202-15. http://dx.doi.org/10.1038/mp.2009.125
73. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 2009;14:359-75. http://dx.doi.org/10.1038/mp.2008.125
74. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. A genome-wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009;66:966-75.
75. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010;167:555-64. http://dx.doi.org/10.1176/appi.ajp.2009.09070932
76. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol 2007;165:1-13. http://dx.doi.org/10.1093/aje/kwj347
77. Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day IN, et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry 2006;11:352-60. http://dx.doi.org/10.1038/sj.mp.4001790
78. Slopien R, Jasniewicz K, Meczekalski B, Warenik-Szymankiewicz A, Lianeri M, Jagodzinski PP. Polymorphic variants of genes encoding MTHFR, MTR, and MTHFD1 and the risk of depression in postmenopausal women in Poland. Maturitas 2008;61:252-5.
79. Lewis SJ, Araya R, Leary S, Smith GD, Ness A. Folic acid supplementation during pregnancy may protect against depression 21 months after pregnancy, an effect modified by MTHFR C677T genotype. Eur J Clin Nutr 2012;66:97-103. http://dx.doi.org/10.1038/ejcn.2011.136
80. Crider KS, Zhu JH, Hao L, Yang QH, Yang TP, Gindler J, et al. MTHFR 677C→T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr 2011;93:1365-72. http://dx.doi.org/10.3945/ajcn.110.004671
81. Roberts SH, Bedson E, Hughes DA, Lloyd KR, Moat S, Pirmohamed M, et al. Folate Augmentation of Treatment - Evaluation for Depression (FolATED): protocol of a randomised controlled trial. BMC Psychiatry 2007;7:65. http://dx.doi.org/10.1186/1471-244X-7-65
82. Roberts SH, Bedson E, Hughes DA, Lloyd KR, Menkes DB, Moat SJ, et al. Erratum: Folate Augumentation of Treatment - Evaluation for Depression (FolATED): protocol of a randomised controlled trial. BMC Psychiatry 2009;9:14. http://dx.doi.org/10.1186/1471-244X-9-14
83. Welsh Assembly Government. Data for the areas identified in the Wales spatial plan, 2010 update. Statistical Bulletin 2010;SB 103/2010.
84. Beck AT, Brown GK, Steer RA. BDI-II Manual. San Antonio, TX: Psychological Corporation; 1996.
85. Russell D, Hoare ZSJ, Whitaker R, Whitaker CJ, Russell IT. Generalised method for adaptive randomisation in clinical trials. Stat Med 2011;30:922-34.
86. Joint Formulary Committee. British National Formulary. British Medical Association and Royal Pharmaceutical Society: biannual. http://www.bnf.org (accessed March 2013).
87. Moat SJ, Doshi SN, Lang D, McDowell IFW, Lewis MJ, Goodfellow J. Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol 2004;287:H1-H7.
88. British Pharmacopoeia. URL: www.pharmacopoeia.co.uk (accessed March 2013).
89. Bailer J, Peigorsch W. Estimating integrals using quadrature methods with an application in pharmacokinetics. Biometrics 1990;46:1201-11. http://dx.doi.org/10.2307/2532462
90. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9. http://dx.doi.org/10.1192/bjp.134.4.382
91. Guy W. Clinical Global Impression (CGI). Taken from ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare; 1976.
92. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. http://dx.doi.org/10.1097/00005650-199603000-00003
93. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
94. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;334(Suppl.):1-100. http://dx.doi.org/10.1111/j.1600-0447.1987.tb10566.x
95. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74. http://dx.doi.org/10.1097/00005650-198601000-00007
96. Sheehan D, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M, et al. Mini International Neuropsychiatric Interview (MINI). English Version 5.0.0 - DSM-IV. Tampa, FL: University of South Florida 2006. URL: www.nccpsychiatry.info/File/MINI500.pdf (accessed March 2013).
97. Parker G, Roy K, Menkes DB, Snowdon J, Boyce P, Grounds D, et al. How long does it take antidepressant therapies to work? Aus N Z J Psychiatry 2000;34:65-70.
98. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157:1423-8. http://dx.doi.org/10.1176/appi.ajp.157.9.1423
99. Gershon S. Antidepressants: can we determine how quickly they work? Psychopharmacol Bull 1995;31:21-2.
100. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006;63:1217-23. http://dx.doi.org/10.1001/archpsyc.63.11.1217
101. European Parliament and Council of the European Union. Directive 2001/20/EC of European Parliament and the Council of 4 April 2001. Official Journal of European Union 2001; Article 2 (Definitions). L121/35-7.
102. Medical Research Council. MRC Guidelines for Good Clinical Practice in Clinical Trials. London: Medical Research Council; 1998.
103. Medical Research Council. A framework for development and evaluation of RCTs for complex interventions to improve health. London: MRC; 2000.
104. Medical Research Council. Good Research Practice. London: MRC; 2000.
105. Department of Health. Research Governance Framework for Health and Social Care. 2nd edn. London: Department of Health; 2005.
106. Wales Office for Research and Development in Health Social Care. Research Governance Framework for Health and Social Care in Wales. Cardiff: Welsh Assembly Government: 2001.
107. Wales Office of Research and Development for Health and Social Care. Research Governance Framework for Health and Social Care in Wales. Cardiff: WORD; 2009.
108. Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med 1998;17:679-96. http://dx.doi.org/10.1002/(SICI)1097-0258(19980315/15)17:5/7%3C679::AID-SIM814%3E3.3.CO;2-O
109. Little R, Rubin D. Statistical Analysis with Missing Data. Chapter 11.5. Chichester: Wiley; 2002.
110. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5. http://dx.doi.org/10.1136/bmj.300.6719.230
111. R project for Statistical Computing. URL: www.r-project.org/(accessed March 2013).
112. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE: 2008.
113. Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess 2005;9(16).
114. Joint Formulary Committee of British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 64th edn. London: RPSGB; 2012.
115. Pricewaterhouse Coopers. Cost of Service Inquiry for Community Pharmacy: Report. London: Pricewaterhouse Coopers LLP; 2011.
116. Department of Health. NHS Reference Costs 2009-10. London: DH; 2010. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459 (accessed March 2013).
117. Department of Health. Prescription Cost Analysis, England 2010. London: DH; 2011. URL: www.ic.nhs.uk/pubs/prescostanalysis2010 (accessed March 2013).
118. Hughes DA, Tilson L, Drummond M. Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations. Pharmacoeconomics 2009;27:635-43. http://dx.doi.org/10.2165/10899570-000000000-00000
119. Curtis L. Unit Costs of Health and Social Care 2010. University of Kent at Canterbury: Personal Social Services Research Unit; 2010.
120. NHS Direct. Board Scorecard 2010/11. London: NHSD; 2011. URL: www.nhsdirect.nhs.uk/CorporateInformation/MinutesOfMeetings/BoardMeetingPapers2011//media/Files/BoardPapers/February2011/Item_71_Board_Scorecard.ashx (accessed March 2013).
121. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. University of York Centre for Health Economics. Discussion Paper 172. York: University of York; 1999.
122. Brazier JE, Roberts JR. Estimation of a preference-based index from the SF-12. Med Care 2004;42:851-9.
123. Dozois DJA, Dobson KS, Ahnberg JL. A psychometric evaluation of the Beck Depression Inventory-II. Psychol Assess 1998;10:83-9. http://dx.doi.org/10.1037//1040-3590.10.2.83
124. Mihaylova B, Briggs A, O'Hagan A, Thompson S. Review of statistical methods for analysing healthcare resources and costs. Health Econ 2011;20:897-916. http://dx.doi.org/10.1002/hec.1653
125. van Asselt AD, van Mastrigt GA, Dirksen CD, Arntz A, Severens JL, Kessels AG. How to deal with cost differences at baseline. Pharmacoeconomics 2009;27:519-28. http://dx.doi.org/10.2165/00019053-200927060-00007
126. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96. http://dx.doi.org/10.1002/hec.944
127. Carr DF, Whiteley G, Alfirevic A, Pirmohamed M. Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenom J 2009; 9:291-305. http://dx.doi.org/10.1038/tpj.2009.29
128. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C→T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003;60:618-26. http://dx.doi.org/10.1001/archpsyc.60.6.618
129. Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC, Giovannucci EL, et al. Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2408-17. http://dx.doi.org/10.1158/1055-9965.EPI-06-0624
130. Levine AJ, Figueiredo JC, Lee W, Conti DV, Kennedy K, Duggan DJ, et al. A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:1812-21. http://dx.doi.org/10.1158/1055-9965.EPI-10-0151
131. Lissowska J, Gaudet MM, Brinton LA, Chanock SJ, Peplonska B, Welch R, et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: population-based case-control study and meta-analyses. Int J Cancer 2007;120:2696-703. http://dx.doi.org/10.1002/ijc.22604
132. Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, et al. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer 2007;120:2452-8. http://dx.doi.org/10.1002/ijc.22565
133. Blanton SH, Henry RR, Yuan Q, Mulliken JB, Stal S, Finnell RH, et al. Folate pathway and nonsyndromic cleft lip and palate. Birth Defects Res A Clin Mol Teratol 2011;91:50-60. http://dx.doi.org/10.1002/bdra.20740
134. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
135. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75. http://dx.doi.org/10.1086/519795
136. SPSS Inc. Predictive Analytic SoftWare (first known as Statistical Package for Social Sciences, then Statistical Product and Service Solutions) Version 18. Chicago, IL: SPSS Inc; 2009. URL: www.spss.com (accessed March 2013).
137. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration; 2011.
138. Mistry H, Buxton M, Longworth L, Chatwin J, Peveler R. Assessing Health Economics of Anti-Depressants team. Comparison of general practitioner records and patient self-report questionnaires for estimation of costs. Eur J Health Econ 2005;6:261-6.
139. Hurst NP, Ruta DA, Kind P. Comparison of the MOS short form-12 (SF-12) health status questionnaire with the SF36 in patients with rhematoid arthritis. Br J Rheumatol 1998;37:862-9. http://dx.doi.org/10.1093/rheumatology/37.8.862
140. Mystakidou K, Tsilika E, Parpa E, Pathiaki M, Galanos A, Vlahos L. The relationship between quality of life and levels of hopelessness and depression in palliative care. Depress Anxiety 2008;25:730-6. http://dx.doi.org/10.1002/da.20319
141. Moat SJ, Madhavan A, Taylor SY, Payne N, Allen RH, Stabler SP, et al. High - but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006; 36:850-9. http://dx.doi.org/10.1111/j.1365-2362.2006.01739.x
142. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84. http://dx.doi.org/10.1002/hec.584
143. Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis - revisited. Health Econ 2013;22:22-34. http://dx.doi.org/10.1002/hec.1812
144. Altman DG, Bland JM. Statistics notes: absence of evidence is not evidence of absence. BMJ 1995;311:485. http://dx.doi.org/10.1136/bmj.311.7003.485
145. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64. http://dx.doi.org/10.1016/S0167-6296(98)00039-3
146. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Åsberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008;24:1329-35. http://dx.doi.org/10.1185/030079908X291958
147. Xie H, Guo J, Wang J, Wang F, Zhao H, Liu C, et al. Glutamate carboxypeptidase II gene polymorphisms and neural tube defects in a high-risk Chinese population. Metab Brain Dis 2012;27:59-65. http://dx.doi.org/10.1007/s11011-011-9272-8
148. Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 2000;9:2837-44. http://dx.doi.org/10.1093/hmg/9.19.2837
149. Ye X, Lai CQ, Crott JW, Troen AM, Ordovas JM, Tucker KL. The folate hydrolase 1561C>T polymorphism is associated with depressive symptoms in Puerto Rican adults. Psychosom Med 2011;73:385-92. http://dx.doi.org/10.1097/PSY.0b013e31821a1ab4
150. Halsted CH, Wong DH, Peerson JM, Warden CH, Refsum H, Smith AD, et al. Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. Am J Clin Nutr 2007;86:514-21.
151. Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP, et al. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res 2008;99:324-32. http://dx.doi.org/10.1016/j.schres.2007.11.013
152. Chamberlin ME, Ubagai T, Mudd SH, Levy HL, Chou JY. Dominant inheritance of isolated hypermethioninemia is associated with a mutation in the human methionine adenosyltransferase 1A gene. Am J Hum Genet 1997;60:540-6.
153. Hazelwood S, Bernardini I, Shotelersuk V, Tangerman A, Guo J, Mudd H, et al. Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/III. Am J Med Genet 1998;75:395-400. http://dx.doi.org/10.1002/(SICI)1096-8628(19980203)75:4%3C395::AID-AJMG9%3E3.0.CO;2-P
154. Uher R, Muthen B, Souery D, Mors O, Jaracz J, Aitchison KJ, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychol Med 2010;40:1367-77. http://dx.doi.org/10.1017/S0033291709991528
155. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-5. http://dx.doi.org/10.1097/00004714-200202000-00007
156. Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v. effectiveness. Br J Psychiatry 2001;179:s9-17. http://dx.doi.org/10.1192/bjp.179.42.s9
157. Hyland K, Shoffner J, Heales SJ. Cerebral folate deficiency. Inherit Metab Dis 2010;33:563-70. http://dx.doi.org/10.1007/s10545-010-9159-6
158. Wu D, Partridge WM. Blood-brain barrier transport of reduced folic acid. Pharm Res 2009;16:415-19.
159. Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonamine modulator and antidepressant-augmenting agent. CNS Spectr 2007;12:739-44.
160. Doshi SN, McDowell IFW, Moat SJ, Payne N, Durant HJ, Lewis MJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanism(s) largely independent of homocysteine lowering. Circulation 2002;105:22-6.
161. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations and clinical issues. J Clin Psychiatr 2009;70(Suppl. 5):12-17. http://dx.doi.org/10.4088/JCP.8157su1c.03
162. Campbell NR. How safe are folic acid supplements? Arch Intern Med 1996;156:1638-44. http://dx.doi.org/10.1001/archinte.156.15.1638
163. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007;85:193-200.
164. North Wales Organisation for Randomised Trials in Health. Standard Operating Procedure for Data Management (NWORTH 6.01). Bangor: NWORTH: 2010.
165. North Wales Organisation for Randomised Trials in Health. Standard Operating Procedure for Statistics (NWORTH 5.02). Bangor: NWORTH: 2010.
166. Edwards RT, Hounsome B, Linck P, Russell IT. Economic evaluation alongside pragmatic randomised trials: developing a standard operating procedure for clinical trials units. Trials 2008;9:64. http://dx.doi.org/10.1186/1745-6215-9-64
167. Hood K, Robling M, Russell IT, et al. Mode of data elicitation, acquisition and response to surveys: a systematic review. Health Technol Assess 2012;16(27).
168. MVH Group. The Measurement and Valuation of Health. Final report on the modelling of valuation tariffs. University of York: Centre for Health Economics; 1995.
169. Gnanadesikan R, Wilk MB. Probability plotting methods for the analysis of data. Biometrika 1965;55:1-17.
170. Shapiro SS, Wilk MB. An analysis of variance test for normality. Biometrika 1965;52:591-611. http://dx.doi.org/10.2307/2333709
171. Shapiro SS, Francia RS. Approximate analysis of variance test for normality. J Am Stat Assoc 1972;67:215-25. http://dx.doi.org/10.2307/2284728
172. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008;26:799-806. http://dx.doi.org/10.2165/00019053-200826090-00009
173. Bowling A. Research Methods in Health: Investigating Health and Health Services. Buckinghamshire, Philadelphia, PA: Open University Press; 2002.
174. St Pierre RG. Using randomized experiments. In Wholey JS, Hatry HP, Newcomer KE, editors. Handbook of Practical Program Evaluation. San Francisco, CA: Jossey-Bass; 2004. p. 150.
175. Bower P, Wilson S, Mathers N. How often do UK primary care trials face recruitment delays? Fam Pract 2007;24:601-3. http://dx.doi.org/10.1093/fampra/cmm051
176. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006;7:9.
177. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999;3(20).
178. Watson JM, Torgerson DJ. Increasing recruitment to randomised trials: A review of randomised controlled trials. BMC Med Res Method 2006;6:34.
179. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, et al. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess 2007;11(48).
180. McDonald AM, Treweek S, Shakur H, Free C, Knight R, Speed C, et al. Using a business model approach and marketing techniques for recruitment to clinical trials. Trials 2011;12:74. http://dx.doi.org/10.1186/1745-6215-12-74
181. Barnard KD, Dent L, Cook A. A systematic review of models to predict recruitment to multicentre clinical trials. BMC Med Res Method 2010;10:63. http://dx.doi.org/10.1186/1471-2288-10-63
182. Bower P, Wallace P, Ward E, Graffy J, Miller J, Delaney B, et al. Improving recruitment to health research in primary care. Fam Pract 2009;26:391-7. http://dx.doi.org/10.1093/fampra/cmp037
183. Goodyear-Smith F, York D, Petousis-Harris H, Turner N, Copp J, Kerse N, et al. Recruitment of practices in primary care research: the long and the short of it. Fam Pract 2009;26:128-36. http://dx.doi.org/10.1093/fampra/cmp015
184. Thomas KS, Koller K, Foster K, Perdue J, Charlesworth L, Chalmers JR. The UK clinical research network: has it been a success for dermatology clinical trials? Trials 2011;12:153. http://dx.doi.org/10.1186/1745-6215-12-153
185. National Institute for Social Care and Health Research. NISCHR Clinical Research Centre (CRC). 2011. URL: www.wales.nhs.uk/sites3/page.cfm?orgid=952&52012 (accessed March 2013).
186. Cox K AM, Wilson E, Elkan R. An evaluation of the introduction of Clinical Trial Officer roles into the cancer clinical trial setting in the UK. Eur J Cancer Care 2005;14:448-56. http://dx.doi.org/10.1111/j.1365-2354.2005.00611.x
187. Stead M, Cameron D, Lester N, Parmar M, Haward R, Kaplan R, et al. Strengthening clinical cancer research in the United Kingdom. Br J Cancer 2011;104:1529-34. http://dx.doi.org/10.1038/bjc.2011.69